thalidomide has been researched along with Brain Edema in 5 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Brain Edema: Increased intracellular or extracellular fluid in brain tissue. Cytotoxic brain edema (swelling due to increased intracellular fluid) is indicative of a disturbance in cell metabolism, and is commonly associated with hypoxic or ischemic injuries (see HYPOXIA, BRAIN). An increase in extracellular fluid may be caused by increased brain capillary permeability (vasogenic edema), an osmotic gradient, local blockages in interstitial fluid pathways, or by obstruction of CSF flow (e.g., obstructive HYDROCEPHALUS). (From Childs Nerv Syst 1992 Sep; 8(6):301-6)
Excerpt | Relevance | Reference |
---|---|---|
"Wallerian degeneration is a potent experimental model for studying reproducible cell proliferation in vivo." | 5.29 | Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration. ( Kögel, B; Schröder, JM; Sellhaus, B; Wöhrmann, T; Zwingenberger, K, 1995) |
"Wallerian degeneration is a potent experimental model for studying reproducible cell proliferation in vivo." | 1.29 | Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration. ( Kögel, B; Schröder, JM; Sellhaus, B; Wöhrmann, T; Zwingenberger, K, 1995) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kwon, HY | 1 |
Han, YJ | 1 |
Im, JH | 1 |
Baek, JH | 1 |
Lee, JS | 1 |
Fan, QY | 1 |
Ramakrishna, S | 1 |
Marchi, N | 1 |
Fazio, V | 1 |
Hallene, K | 1 |
Janigro, D | 1 |
Rigual, D | 1 |
Qiu, J | 1 |
Fenstermaker, RA | 1 |
Fabiano, AJ | 1 |
Tan, DS | 1 |
Evanson, J | 1 |
Plowman, PN | 1 |
Chew, SL | 1 |
Schröder, JM | 1 |
Sellhaus, B | 1 |
Wöhrmann, T | 1 |
Kögel, B | 1 |
Zwingenberger, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Efficacy and Safety of Thalidomide in the Adjuvant Treatment of Moderate New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273529] | Phase 2 | 100 participants (Anticipated) | Interventional | 2020-02-20 | Not yet recruiting | ||
The Efficacy and Safety of Thalidomide Combined With Low-dose Hormones in the Treatment of Severe New Coronavirus (COVID-19) Pneumonia: a Prospective, Multicenter, Randomized, Double-blind, Placebo, Parallel Controlled Clinical Study[NCT04273581] | Phase 2 | 40 participants (Anticipated) | Interventional | 2020-02-18 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
5 other studies available for thalidomide and Brain Edema
Article | Year |
---|---|
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Two cases of immune reconstitution inflammatory syndrome in HIV patients treated with thalidomide.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiretroviral Therapy, Highly Active; Brain Edema; Do | 2019 |
Combined effects of prenatal inhibition of vasculogenesis and neurogenesis on rat brain development.
Topics: Aging; Animals; Animals, Newborn; Blood Vessels; Blood-Brain Barrier; Brain; Brain Chemistry; Brain | 2008 |
Tumoral Bing-Neel Syndrome presenting as a cerebellar mass.
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplas | 2013 |
Post-radiation inflammatory reaction controlled with thalidomide and rofecoxib.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Brain Edema; Brain Neoplasms; Female; Hemangioblasto | 2004 |
Inhibitory effects of thalidomide on cellular proliferation, endoneurial edema and myelin phagocytosis during early wallerian degeneration.
Topics: Animals; Brain Edema; Cell Division; Myelin Sheath; Phagocytosis; Rats; Rats, Wistar; Schwann Cells; | 1995 |